Abstract FR401: Lorundrostat Mitigates Cardiorenal Injury Independent of Blood Pressure Reduction in an L-NAME/Angiotensin II Rat Model
Hypertension · 2026-10 · 83 (Suppl_1)
DOI: 10.1161/hyp.83.suppl_1.fr401 ↗Kurz gefasst
Fachartikel in der Zeitschrift Hypertension, 2026-10. Verfasst von WEI CHUNG CHEN und 10 weiteren Autor:innen.
Abstract (Originalsprache)
Inappropriate aldosterone ( ALDO ) levels and activation of the mineralocorticoid receptor ( MR ) have been linked to cardiac and renal damage. However, no studies have shown that simply lowering ALDO levels has the same beneficial effects on cardiac and renal damage as an MR antagonist. Lorundrostat, a novel ALDO synthase inhibitor ( ASI ), successfully reduced blood pressure ( BP ) in individuals with uncontrolled hypertension who were taking at least two medications and decreased albuminuria in patients with chronic kidney disease. However, the impact of Lorundrostat on cardiorenal damage is unknown. We studied a hypertensive rodent model of MR-mediated cardiorenal damage induced by L-NAME and Angiotensin II ( AngII ), independent of BP reduction. This model closely resembles the characteristics observed in treatment-resistant hypertension, including elevated BP, reduced nitric oxide ( NO )-mediated vasodilation, increased vasoconstriction, and vascular inflammation. In brief, rodents are fed a high-salt diet (1.6% sodium) and treated with L-NAME (0.2 mg/mL in drinking water) to suppress endothelial NO synthase activation for 14 days. For the final three days, AngII (225 ug/kg/day via subcutaneous minipump infusion on days 12-14) is administered. This model induces rapid cardiorenal damage after 14 days of treatment, which leads to severe renal failure and/or stroke if left untreated. We studied male Wistar rats (8-10 weeks old) consuming a high-salt diet (1.6% sodium) and randomly assigned them to the following conditions for 14 days: 1 ) Control; 2 ) L-NAME/AngII; 3 ) L-NAME/AngII + Eplerenone (100 mg/kg/day PO); 4 ) L-NAME/AngII + Lorundrostat (10 mg/kg/day PO); 5 ) L-NAME/AngII + Lorundrostat (30 mg/kg/day PO); 6 ) L-NAME/AngII + Lorundrostat (100 mg/kg/day PO). Rats treated with L-NAME/AngII showed greater myocardial injury, renal inflammation, urinary ALDO excretion, kidney injury molecule-1 ( KIM-1 ) excretion, albuminuria, and BP than controls (ANOVA, p
Zitieren
APA
CHEN, W. C., Qrisha, Y., karimian, M., Rivera, A., Mitchell, R. N., Pojoga, L. H., Gunawardhana, K., Tortorici, M., Rodman, D., Williams, G. H., & Romero, J. (2026). Abstract FR401: Lorundrostat Mitigates Cardiorenal Injury Independent of Blood Pressure Reduction in an L-NAME/Angiotensin II Rat Model. Hypertension, 83(Suppl_1). https://doi.org/10.1161/hyp.83.suppl_1.fr401
Vancouver
CHEN WC, Qrisha Y, karimian M, Rivera A, Mitchell RN, Pojoga LH, et al. Abstract FR401: Lorundrostat Mitigates Cardiorenal Injury Independent of Blood Pressure Reduction in an L-NAME/Angiotensin II Rat Model. Hypertension. 2026;83(Suppl_1). doi:10.1161/hyp.83.suppl_1.fr401
BibTeX
@article{CHEN2026,
author = {CHEN, WEI CHUNG and Qrisha, Yashini and karimian, Maryam and Rivera, Alicia and Mitchell, Richard N. and Pojoga, Luminita H and Gunawardhana, Kushan and Tortorici, Michael and Rodman, David and Williams, Gordon H and Romero, Jose},
title = {Abstract FR401: Lorundrostat Mitigates Cardiorenal Injury Independent of Blood Pressure Reduction in an L-NAME/Angiotensin II Rat Model},
journal = {Hypertension},
year = {2026},
volume = {83},
number = {Suppl_1},
doi = {10.1161/hyp.83.suppl_1.fr401}
}
EUVIMED